信达生物(01801.HK)获摩根大通增持123.37万股

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 1.2337 million shares at an average price of HKD 78.6975 per share, totaling approximately HKD 97.0865 million [1] - Following this acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87.9149 million shares, increasing its ownership percentage from 4.99% to 5.06% [1]